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Abstract
Background. The interest in n-3 polyunsaturated fatty acids (PUFAs) has expanded signiﬁcantly in the last few years, due to
their many positive effects described. Consequently, the interest in ﬁsh oil supplementation has also increased, and many
different types of ﬁsh oil supplements can be found on the market. Also, it is well known that these types of fatty acids are very
easily oxidized, and that stability among supplements varies greatly.
Aims of the study. In this pilot study we investigated the effects of two different types of natural ﬁsh oils containing different
amounts of the n-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and antioxidants on plasma and
brain fatty acids, blood lipids, vitamin E, and in vivo lipid peroxidation, as well as brain nitric oxide synthase (NOS) activity, an
enzyme which has been shown to be important for memory and learning ability.
Methods. Sprague-Dawley rats were divided into four groups and fed regular rat chow pellets enriched with 5% (w/w) of butter
(control group), a natural ﬁsh oil (17.4% EPA and 11.7% DHA, referred to as EPA-rich), and a natural ﬁsh oil rich in DHA
(7.7% EPA and 28.0% DHA, referred to as DHA-rich). Both of the ﬁsh oils were stabilized by a commercial antioxidant
protection system (Pufanox
 ) at production. The fourth group received the same DHA-rich oil, but without Pufanox
 
stabilization (referred to as unstable). As an index of stability of the oils, their peroxide values were repeatedly measured during
9 weeks. The dietary treatments continued until sacriﬁce, after 10 days.
Results. Stability of the oils varied greatly. It took the two stabilized oils 9 weeks to reach the same peroxide value as the
unstable oil reached after only a few days. Both the stabilized EPA- and DHA-rich diets lowered the triacylglycerols and
total cholesterol compared to control (-45%, P < 0.05 and -54%, P < 0.001; -31%, P < 0.05 and -25%, P < 0.01) and so did
the unstable oil, but less efﬁciently. Only the unstable oil increased in vivo lipid peroxidation signiﬁcantly compared to
control (+40%, P < 0.001). Most of the fatty acids in the plasma phospholipids were signiﬁcantly affected by both the
EPA- and DHA-rich diets compared to control, reﬂecting their speciﬁc fatty acid pattern. The unstable oil diet resulted
in smaller changes, especially in n-3 PUFAs. In the brain phospholipids the changes were less pronounced, and only the
diet enriched with the stabilizedD H A - r i c ho i lr e s u l t e di nas i g n i ﬁcantly greater incorporation of DHA (+13%, P < 0.01),
as well as total n-3 PUFAs (+13%, P < 0.01) compared to control. Only the stabilized DHA-rich oil increased the brain
NOS activity (+33%, P < 0.01).
Conclusions. Both the EPA- and DHA-rich diets affected the blood lipids in a similarly positive manner, and they both had a
large impact on plasma phospholipid fatty acids. It was only the unstable oil that increased in vivo lipid peroxidation. However,
the intake of DHA was more important than that of EPA for brain phospholipid DHA enrichment and brain NOS activity, and
the stability of the ﬁsh oil was also important for these effects.
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In the last few years, the interest in n-3 polyunsatu-
rated fatty acids (PUFAs) has expanded signiﬁcantly
due to the many positive effects described. As a con-
sequence, the interest in ﬁsh oil supplementation
has also increased considerably, and many studies
have demonstrated the beneﬁts to different condi-
tions, including cardiovascular (1,2), neurological,
and psychiatric disorders (3). Many different types
of ﬁsh oil supplements can be found on the market,
but studies comparing them are rare. In this pilot
study we aimed at investigating two different types of
ﬁsh oils containing high amounts of either the n-3
PUFA eicosapentaenoic acid (EPA) or docosahexae-
noic acid (DHA). They were both of natural origin
and thus not chemically modiﬁed to contain the pure
fatty acid. Besides cardiovascular markers, we also
studied the brain for fatty acids and nitric oxide syn-
thase (NOS) activity. This enzyme has been shown to
be of critical importance for memory and learning
ability (4–9).
It is also well known that these highly unsaturated
fatty acids are highly susceptible to oxidation, thereby
making the production of a stable ﬁsh oil very difﬁcult
(10). Consequently, the stability among supplements
varies greatly (11). Several studies have shown that
intake of an unstable oil can induce lipid peroxida-
tion which may affect the results negatively and may
even produce adverse effects (12–14). Thus, in order
to elucidate the importance of in vitro stability of
the ﬁsh oil for in vivo effects, we included one of
the oils (the DHA-rich) which had been treated dif-
ferently at production as it was not stabilized by a
sufﬁcient amount of antioxidants and consequently
was shown to be unstable.
Materials and methods
Animals and diets
Male pathogen-free Sprague-Dawley rats (n = 24)
weighing 250-350 g were fed standard pellet diets
containing 57% carbohydrates, 17% protein, 1.4% fat,
and 74 mg vitamin E/kg. The standard pellet diets
were enriched with 5% (w/w) of butter (control, n = 6)
or with 5% (w/w) of three different ﬁsh oil prepara-
tions as follows: One group of rats (n = 6) received a
natural ﬁsh oil rich in EPA (referred to as EPA-rich
oil). Another group of rats (n = 6) received a natural
ﬁsh oil rich in DHA (referred to as DHA-rich oil).
These oils were stabilized with an antioxidant pro-
tection system (Pufanox
 ) in exactly the same way.
The last group (n = 6) received the same DHA-rich oil
as the third group did, but without the antioxidant
protection system. The four different groups are
referred to as control, stabilized EPA-rich oil, stabi-
lized DHA-rich oil, and unstable DHA-rich oil. All
diets were stored in sealed containers under nitrogen
at 4C in the dark and supplied to the animals once
daily. After 10 days the rats were weighed, anaesthe-
tized with pentobarbital sodium (60 mg/kg body
weight) given intraperitoneally, and then killed by
exsanguination. Plasma was prepared immediately by
centrifugation of the EDTA-rich blood for 15 min
at 500 g at 4C, and then stored at -70C. The brain
was excised, weighed, divided into smaller pieces,
and stored at -70C.
Fish oil and antioxidant compositions
Both ﬁsh oils were natural and had not been chem-
ically modiﬁed. The EPA-rich oil (ESKIMO-3,
Cardinova,Uppsala,Sweden)wasobtainedfrom small
sardines living in cold deep water, and it represents
a DHA:EPA ratio normally found in a typical, not
chemically altered, natural ﬁsh oil. The DHA-rich
oil (EPAX 0525TG, Pronova, Oslo, Norway) was
obtained from the eyes of tuna ﬁsh. The fatty acid
compositions, as assayed by gas-liquid chromato-
graphy, of the different ﬁsh oils and butter are shown
in Table I. The supplements contained approximately
equal amounts of monounsaturated and n-6 fatty
acids. The saturated fat in the control (butter) diet
was replaced by n-3 PUFAs in the ﬁsh oil diets. The
cholesterol concentration was less than 3 mg/g both
in the butter and ﬁsh oil supplements. The EPA-rich
oil (ESKIMO-3) was stabilized using a commercial
natural antioxidant mixture (Pufanox
 , Cardinova,
Uppsala, Sweden) which includes tocopherols and
vitamin C among other components. The DHA-rich
oil was stabilized in exactly the same way (Cardinova,
Uppsala, Sweden). The ﬁnal d-a-tocopherol con-
centration in the stabilized oils was 3.5 IU/g. The
unstabilizedoilcontainedtheoriginalconcentrationof
0.75 IU d-a-tocopherol/g. The butter contained 0.03
IU d-a-tocopherol/g. As an index of the stability of the
oils,theperoxidevalueswererepeatedlymeasureddur-
inga2-monthperiod. Theoilswere stored inthedark,
in open beakers, and at room temperature. The per-
oxidevaluesweremeasuredaccordingtoAmericanOil
Chemists' Society (AOCS) Ofﬁcial Method Ca 18-90.
Analyses of blood samples
Blood lipoproteins (total cholesterol and triacylglycer-
ols) were measured immediately after blood sampling,
using enzymatic methods.
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xidation, lipoperoxides (generated in vivo as a
result of oxygen free-radical-induced lipid peroxi-
dation) were hydrolysed, and the products includ-
ing malondialdehyde (MDA) were reacted with
thiobarbituric acid (TBA). The resulting MDA-
(TBA)2 was measured by reversed phase high-
performance liquid chromatography (RP-HPLC).
The method has been described previously (15);
however, some modiﬁcations were made as
described elsewhere (16). The results are exp-
ressed as mmol/L MDA equivalents.
For measurements of plasma a-tocopherol concen-
trations, a RP-HPLC system was used. The samples
were treated according to Öhrvall et al. (17). For
detection an ultraviolet (UV), instead of ﬂuoresc-
ence, detector was employed (AOCS Ofﬁcial
Method Ce 8-89, 1990).
For measurement of fatty acids, lipids in plasma or
brain homogenates (all brains were prepared by the
same person and extracted from the same location
of cerebral cortex) were extracted with chloroform/
methanol and submitted to thin-layer chromatogra-
phy (TLC), and the phospholipids were subsequently
recovered after evaluation of the plate. After hydro-
lysis and transmethylation, the fatty acid methyl esters
were separated by gas-liquid chromatography as pre-
viously described (18).
Analyses of brain NOS
The NOS activity in brain homogenates was mea-
sured by monitoring the conversion of (
3H)arginine
to (
3H)citrulline as described earlier (19). Brieﬂy, the
reaction mixture consisted of 100 mg of brain homo-
genate and 100 mLo f(
3H)arginine (100 nmol/L) to
1 ml of buffer containing 50 mmol/L Hepes (pH 7.4),
1 mmol/L NADPH, 1 mmol/L EDTA, 1.25 mmol/L
CaCl2, 1 mmol/L dithiothreitol, and 10 mg/mL cal-
modulin. After incubation for 30 min at 37C, the
reaction was terminated, and 1 ml of the mixture
was applied to Dowex AG50WX-8 (Na+ form,
Dow Pharmaceuticals Co., Midland, MI) columns
(Bio-Rad, Hercules, CA) and eluted with 2 ml of dis-
tilled water.
3H-L-citrulline was counted, and NOS
activity was expressed as nmol/mg protein. Total
protein content was quantiﬁed by bicinchoninic
acid (BCA) protein assay kit (Pierce, Rockford, IL).
Statistical methods
The SPSS 10.1 software package (SPSS, Inc.,
Chicago, Illinois, USA) was used for the statistical
analyses. Multiple comparisons were made by one-
way ANOVA followed by the post hoc least square
(LSD) test. P-values <0.05 were adopted as signiﬁ-
cant. Data are presented as mean ± SD.
Results
Stability of the ﬁsh oils
There was a striking difference in the peroxide values
of the unstable and the Pufanox-stabilized oils; the
unstable oil started at 2 mEq/kg and reached a per-
oxide value of 23 mEq/kg after 1 week and 47 mEq/kg
after 2 weeks. No further measurement was made
on this oil. The two stabilized oils started both at
1 mEq/kg, and after 1 week both oils had reached
2 mEq/kg, and after 2 weeks the DHA-rich oil had
TableI. Fatty acid composition of the supplements.
a
Fatty acid
b
Supplement
Butter EPA-rich oil DHA-rich oil
4:0-12:0 14.6 - -
14:0 11.1 8.3 4.2
16:0 27.4 15.2 19.2
18:0 10.5 2.6 4.3
Total saturated 63.6 26.9 28.6
16:1(n-7) 3.1 9.1 7.0
18:1(n-7+n-9) 23.6 11.2 14.5
20:1(n-9) - 1.1 1.2
Total monounsaturated 26.7 22.6 23.1
18:2(n-6) 2.6 1.2 1.6
16:3(n-4) - 1.8 1.0
16:4(n-3) - 3.2 -
18:4(n-3) - 3.4 1.2
20:4(n-6) AA
c - 1.0 2.2
22:4(n-3) - - 1.8
20:5(n-3) EPA - 17.4 7.7
22:5(n-3) - 2.1 1.0
22:6(n-3) DHA - 11.7 28.0
Total (n-6) PUFAs 2.6 2.3 3.8
Total (n-3) PUFAs - 40.2 40.9
Ratio EPA:total (n-3) - 0.4 0.2
Ratio DHA:total (n-3) - 0.3 0.7
aIn g/100 g total fatty acids. The standard pellet diet (1.4% fat, w/w)
was enriched with 5% (w/w) butter (control) or ﬁsh oils. The fatty
acid composition of the butter was reported by the manufacturer.
bOnly fatty acids ‡1.0 g/100 g total fatty acids are shown.
cArachidonic acid.
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at 2 mEq/kg. After 9 weeks the DHA-rich oil had
reached 29 and the EPA-rich oil 14 mEq/kg.
Food intake, weight gain, plasma lipids, a-tocopherol
concentration, and lipid peroxidation
Food intake and weight gain did not differ among ani-
mals fed the different diets (data not shown). Plasma
triacylglycerol and total cholesterol concentrations
were signiﬁcantly lower in the groups fed ﬁsh oils than
in the control group (Table II). Plasma a-tocopherol
concentrations were higher in rats fed the two sta-
bilized ﬁsh oils compared to control (Table II). The
plasma MDA concentration was signiﬁcantly higher
after feeding the unstable DHA-rich oil diet com-
pared to the other diets (Table II).
Plasma phospholipid fatty acid composition
Signiﬁcant differences in the compositions of plasma
phospholipids between rats in the control group and
those fed the different ﬁsh oil diets were seen for
several fatty acids (Table III). Feeding the stabilized
EPA-rich oil diet resulted in the highest proportions
of EPA and total n-3 PUFAs, and the lowest propor-
tions of total n-6 fatty acids, whereas the DHA-rich
oil diet resulted in the highest proportions of DHA.
A difference between feeding the stabilized DHA-
rich oil, compared to the unstable, was a signiﬁcantly
higher proportion of both DHA and total n-3 PUFAs
after intake of the stabilized oil. The EPA-rich oil diet
resulted in the lowest n-6:n-3 ratio which was signif-
icantly different from both DHA-rich oil diets.
Brain phospholipid fatty acid composition
Relative to the plasma phospholipid fatty acids, only
minor differences could be observed in the brain
phospholipid fatty acids compared to control
(Table IV). Only the stabilized DHA-rich oil diet
resulted in a signiﬁcant increase in DHA and total
n-3 PUFAs compared to the control diet. All ﬁsh oil
diets showed a signiﬁcant decrease in total n-6 fatty
acids and n-6:n-3 ratio compared to control.
Brain nitric oxide synthase activity
A signiﬁcantly higher NOS activity in the brain was
found in the group fed the stabilized DHA-rich oil
diet compared to the other groups (Figure 1).
Discussion
In this study both the EPA- and DHA-rich oil diets
affected the blood lipids in a similarly positive manner
(Table II), which has also been reported in studies
using pure EPA and DHA oils in humans (20,21).
The lipid peroxidation of plasma (MDA) was sig-
niﬁcantly increased only after intake of the unstable
ﬁsh oil (Table II). It has been shown that most
commercial ﬁsh oils become rancid after only a few
days owing to their deﬁcient antioxidant stabiliza-
tion (11). Also, highly concentrated and chemically
modiﬁed ﬁsh oils are usually more unstable than
natural ﬁsh oils. An unstable oil may consume anti-
oxidants such as vitamin E in the body, and induce
formation of free radicals leading to lipid peroxida-
tion and cellular injury (10–13,22). The unstable ﬁsh
oils can also increase blood glucose levels, probably
due to lipid peroxidation in the pancreas, resulting in
decreased insulin production (23). A study in humans
found that the plasma lipid peroxidation induced by
intake of an unstable ﬁsh oil was not inhibited by
simultaneous intake of even high doses of vitamin E
(24). Also in animals, vitamin E does not appear to
provide sufﬁcient protection to diets high in n-3
PUFAs (10). Although there is concern that ﬁsh oils
TableII. Plasma triacylglycerols, plasma total cholesterol, plasma a-tocopherol and plasma MDA in rats fed the different ﬁsh oil-enriched
diets. Data are expressed as mean ± SD.
Control Stabilized EPA-rich oil Stabilized DHA-rich oil Unstable DHA-rich oil
Triacylglycerols (mmol/L) 1.1 ± 0.4 0.6 ± 0.2
a 0.5 ± 0.1
b 0.7 ± 0.2
a
Total cholesterol (mmol/L) 1.6 ± 0.2 1.1 ± 0.1
c 1.2 ± 0.1
c 1.3 ± 0.1
b,d
a-Tocopherol (mmol/mmol total lipids) 7.8 ± 0.9 8.7 ± 0.8 8.2 ± 0.6 7.0 ± 0.7
d
MDA (mmol/L) 0.5 ± 0.0 0.6 ± 0.0 0.6 ± 0.1 0.7 ± 0.1
c,d,e
aP < 0.05 versus control.
bP < 0.01 versus control.
cP < 0.001 versus control.
dP < 0.05 versus stabilized EPA-rich oil.
eP < 0.01 versus stabilized DHA-rich oil.
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date are inconclusive (10,25). This might reﬂect that
oils of different stability and in different dosages are
used in the studies. Also storage and handling during
the supplementation period might differ, as well as
methods used to measure the oxidation.
Most of the plasma phospholipid fatty acids in this
study were signiﬁcantly affected by both the EPA- and
DHA-rich oil diets compared to control, reﬂecting
their speciﬁc fatty acid pattern (Table III). The unsta-
ble DHA-rich oil diet, compared to the stabilized one,
resulted in less increase in the n-3 PUFAs. This could
possibly reﬂect lipid peroxidation and is in accordance
withtheobservedincreaseinplasmalipidperoxidation
(MDA) in the group consuming the unstable ﬁsh oil
diet. Compared to the plasma phospholipids, changes
in the brain phospholipids (Table IV) were much
smaller, indicating a resistance towards modiﬁcation.
Only the diet enriched with the DHA-rich oil, com-
pared to the EPA-rich oil, resulted in a signiﬁcantly
greater incorporation of DHA as well as total n-3
PUFAsinbrainphospholipids.Theareascorrespond-
ingtothefattyacidEPAintheanalyseswereverysmall
in the samples from brain (corresponding to <0.1 g/
100gtotalfattyacids),andhadapproximatelythesame
area in all ﬁsh oil diet groups, but were absent in the
controlgroup.BycomparingtheratiosofEPA:totaln-
3 and DHA:total n-3 of the two ﬁsh oils (Table I) it is
evident that the DHA-rich oil contained relatively
more of its speciﬁc fatty acid DHA than the EPA-
richoilcontainedEPA.Thiscouldhaveinﬂuencedthe
enrichment of EPA and DHA in the phospholipids in
the two groups (EPA-rich oil diet group versus DHA-
rich oil diet group) and is a drawback of not using the
pure fatty acids. Synergistic effects of different fatty
acids in a blend are also plausible.
The DHA content of brain is much higher than
the EPA content, and DHA is a major constituent
of neuronal membrane phospholipids. Since the
membrane phospholipid fatty acid composition is
important for the conﬁguration and function of neu-
rotransmitter receptors, DHA has been suggested
TableIII. Plasma phospholipid fatty acid composition in rats fed the different ﬁsh oil-enriched diets. Data are expressed as mean ± SD.
Fatty acid
a Control Stabilized EPA-rich oil Stabilized DHA-rich oil Unstable DHA-rich oil
C16:0 21.1 ± 0.9 23.2 ± 1.1
c 23.4 ± 0.6
c 22.7 ± 1.4
b
C18:0 19.6 ± 0.6 18.6 ± 0.7 17.9 ± 1.0
b 18.2 ± 1.3
b
C24:0 0.7 ± 0.1 0.5 ± 0.0
c 0.6 ± 0.1
b 0.7 ± 0.1
e
Total saturated 41.8 ± 0.9 42.9 ± 0.8 42.4 ± 1.0 42.1 ± 2.1
C16:1(n-7) 0.8 ± 0.2 0.9 ± 0.2 0.6 ± 0.2 0.6 ± 0.2
C18:1(n-9) 4.7 ± 0.6 4.2 ± 0.3
b 4.2 ± 0.2
b 4.2 ± 0.2
b
C18:1(n-7) 2.6 ± 0.6 2.7 ± 0.2 2.1 ± 0.3
b,f 2.1 ± 0.1
b,f
C24:1(n-9) 0.8 ± 0.4 1.1 ± 0.1
b 0.8 ± 0.1
e 0.9 ± 0.2
Total monounsaturated 8.9 ± 0.9 9.0 ± 0.5 7.8 ± 0.5
c,f 7.9 ± 0.3
c,f
C18:2(n-6) 24.7 ± 1.1 17.1 ± 3.7
d 18.1 ± 1.4
d 18.7 ± 1.6
d
C20:3(n-6) 1.5 ± 0.3 0.7 ± 0.3
c 1.0 ± 0.4
b 0.5 ± 0.4
d,h
C20:4(n-6) Arachidonic acid 12.2 ± 1.3 9.3 ± 0.8
d 12.4 ± 0.6
g 10.7 ± 1.2
b,e,h
C20:5(n-3) EPA 0.7 ± 0.1 7.4 ± 0.8
d 2.5 ± 0.4
d,g 2.7 ± 0.5
d,g
C22:5(n-3) 0.7 ± 0.2 1.8 ± 0.3
d 1.0 ± 0.1
g 0.8 ± 0.1
g
C22:6(n-3) DHA 5.6 ± 0.4 8.1 ± 0.6
d 12.7 ± 0.5
d,g 11.1 ± 0.6
d,g,j
Total (n-6) PUFAs 38.4 ± 1.0 27.1 ± 0.8
d 31.5 ± 1.4
d,f 29.9 ± 2.6
d
Total (n-3) PUFAs 7.0 ± 0.4 17.3 ± 0.9
d 16.2 ± 0.4
d,f 14.6 ± 0.8
d,g,i
Ratio (n-6):(n-3) 5.5 ± 0.3 1.6 ± 0.1
d 1.9 ± 0.1
d,f 2.0 ± 0.2
d,f
aOnly fatty acids >0.5 g/100 g total fatty acids are shown.
bP < 0.05 versus control.
cP < 0.01 versus control.
dP < 0.001 versus control.
eP < 0.05 versus stabilized EPA-rich oil.
fP < 0.01 versus stabilized EPA-rich oil.
gP < 0.001 versus stabilized EPA-rich oil.
hP < 0.05 versus stabilized DHA-rich oil.
iP < 0.01 versus stabilized DHA-rich oil.
jP < 0.001 versus stabilized DHA-rich oil.
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tion (26,27). Accordingly, fatty acid preparations with
high DHA content have shown a beneﬁcial effect on
brain function (26–28). For example, it has been
shown that the intake of DHA, not EPA, among
pregnant women is important for the intelligence
of the child when tested at 4 years of age (29), and
intake of DHA, but not EPA, has been shown to
be associated with reduced risk of Alzheimer’sd i s -
ease (30). EPA is the precursor of eicosanoids
which have important functions as secondary mes-
sengers and neuromodulators (31), inhibits cyclo-
oxygenase-2 (32), and has an effect on gene
expression (33). Furthermore, EPA is an inhibitor
of phospholipase A2 and may thereby decrease the
release of fatty acids such as DHA from the phospho-
lipids in the cell membrane (34). Some psychiatric
disorders, such as schizophrenia, are characterized
by increased activity of phospholipase A2 (35,36).
Peet et al. (36) found an improvement in schizo-
phrenic patients by EPA, but not by DHA,
administration. Also, several studies have reported
improvements in children with neuropsychiatric pro-
blems supplemented with an EPA-rich ﬁsh oil; how-
ever, the results have not been consistent (3,37–39).
Administration of n-3 PUFAs has been shown to
improve learning ability and memory in rats and mice
(40–42), and several studies have found brain NOS
activity to be of crucial importance to this cognitive
ability (4–9). It has been shown in piglets that supple-
mentation with DHA signiﬁcantly enhances NOS
activity in the brain (43). This study in rats points
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Figure1. Brainnitricoxide synthase (NOS)activity(asL-citrulline,
pmol/mg protein) in rats fed the different ﬁsh oil-enriched diets.
Data are expressed as mean ± SD. **P < 0.01 versus control;
++P < 0.01 versus stabilized EPA-rich oil;
OP < 0.05 versus unstable
DHA-rich oil (EPA = eicosapentaenoic acid; DHA = docosahex-
aenoic acid).
TableIV. Brain phospholipid fatty acid composition in rats fed the different ﬁsh oil-enriched diets. Data are expressed as mean ± SD.
Fatty acid
a Control Stabilized EPA-rich oil Stabilized DHA-rich oil Unstable DHA-rich oil
C16:0 24.3 ± 0.7 25.3 ± 1.7 25.6 ± 1.4 24.4 ± 2.8
C18:0 17.2 ± 0.6 17.7 ± 0.9 17.3 ± 0.6 16.8 ± 1.0
Total saturated 43.2 ± 0.9 44.7 ± 1.5 44.4 ± 1.5 44.3 ± 1.5
C16:1(n-7) 1.1 ± 0.3 1.2 ± 0.2 1.4 ± 0.1 1.2 ± 0.3
C18:1(n-9) 17.6 ± 1.3 17.0 ± 2.0 16.8 ± 0.4 18.4 ± 2.2
C18:1(n-7) 3.6 ± 0.3 3.4 ± 0.3 3.5 ± 0.3 3.6 ± 0.4
C20:1(n-9) 1.8 ± 0.4 1.4 ± 0.2
b 1.4 ± 0.1
b 1.5 ± 0.3
C24:1(n-9) 0.8 ± 0.2 0.5 ± 0.2
b 0.6 ± 0.0 0.6 ± 0.1
Total monounsaturated 25.4 ± 1.8 23.5 ± 1.6 24.2 ± 0.7 25.4 ± 1.8
C18:2(n-6) 0.6 ± 0.0 0.5 ± 0.0 0.5 ± 0.0 0.5 ± 0.1
C20:4(n-6) Arachidonic acid 9.1 ± 1.0 8.3 ± 0.8 8.6 ± 0.4 8.1 ± 1.3
C22:4(n-6) 2.9 ± 0.4 2.6 ± 0.2
b 2.5 ± 0.2
b 2.4 ± 0.2
c
C22:6(n-3) DHA 13.5 ± 1.0 14.0 ± 1.1 15.2 ± 0.7
c,e 14.4 ± 0.9
Total (n-6) PUFAs 12.6 ± 1.3 11.4 ± 0.4
d 11.6 ± 0.6
b 11.0 ± 0.3
b
Total (n-3) PUFAs 13.5 ± 1.0 14.0 ± 1.1 15.2 ± 0.7
c,e 14.4 ± 0.9
Ratio (n-6):(n-3) 0.9 ± 0.1 0.8 ± 0.0
c 0.8 ± 0.0
d 0.8 ± 0.0
d
aOnly fatty acids >0.5 g/100 g total fatty acids are shown.
bP < 0.05 versus control.
cP < 0.01 versus control.
dP < 0.001 versus control.
eP < 0.05 versus stabilized EPA-rich oil.
Fish oils: effect in rats 211to DHA as an essential constituent of a ﬁsh oil for
improvement of brain DHA content and brain NOS
activity. However, studies performed by us on the
relaxation of vascular tissue in rats have shown that
an EPA-rich oil is the most efﬁcient (44). Thus,
depending on what is under investigation, the optimal
effect may be met by ﬁsh oils of different DHA:EPA
ratios.Thisstudyalsofoundthatnotonlythefattyacid
content but also the stability, and thus the antioxidant
content, of the ﬁsh oil was important to brain DHA
concentration and NOS activity.
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